Oncology
Revealing the molecular mechanism of tumor development and identifying the matching inhibitory candidates is one important area within the cancer research.
The tumor diversity is extremely high. Therefore, cancer research belongs to the high variant research areas with manifold scientific approaches.
To match this challenge, we offer you a unique diversity of products for your oncology research and development in the academic and pharmaceutical field.
Click on the organs and learn more about cancer types
General information
Oncologists focus on the diagnosis, therapy and follow-up of cancer.
Cancer is a class of diseases in which cells start to divide uncontrollably and invade other tissues. Cancer cells can spread to other parts of the body via the blood and lymphatic system. Under physiological conditions, cell proliferation is tightly controlled by many mechanisms. In addition, the immune system is able to recognize and destroy cancer cells. If these mechanisms fail or the immune system cannot effectively destroy the cells, it can lead to a malignant tumor. Theoretically, a malignant neoplasm can occur everywhere, but there are cancers that are more often than others. For men it is the prostate and in women it is the mammary gland.
Relevant products for oncology research
Name | Price | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anti-HLA-DRA antibody (100-180 aa) (STJ192452) | Login | Anti-HLA-DRA antibody (100-180 aa) (STJ192452) | ||||||||||||||||
|
||||||||||||||||||
Anti-SLAMF8 antibody (110-190 aa) (STJ192455) | Login | Anti-SLAMF8 antibody (110-190 aa) (STJ192455) | ||||||||||||||||
|
||||||||||||||||||
Anti-STUB1 antibody (160-240 aa) (STJ192459) | Login | Anti-STUB1 antibody (160-240 aa) (STJ192459) | ||||||||||||||||
|
||||||||||||||||||
Anti-EGFL7 antibody (140-220 aa) (STJ192463) | Login | Anti-EGFL7 antibody (140-220 aa) (STJ192463) | ||||||||||||||||
|
||||||||||||||||||
Anti-TLR9 antibody (400-480 aa) (STJ192464) | Login | Anti-TLR9 antibody (400-480 aa) (STJ192464) | ||||||||||||||||
|
||||||||||||||||||
Anti-DLL3 antibody (510-590 aa) (STJ192465) | Login | Anti-DLL3 antibody (510-590 aa) (STJ192465) | ||||||||||||||||
|
||||||||||||||||||
Anti-PRLR antibody (80-160 aa) (STJ192473) | Login | Anti-PRLR antibody (80-160 aa) (STJ192473) | ||||||||||||||||
|
||||||||||||||||||
Anti-CRNN antibody (380-460 aa) (STJ192475) | Login | Anti-CRNN antibody (380-460 aa) (STJ192475) | ||||||||||||||||
|
||||||||||||||||||
Anti-C1QTNF4 antibody (40-120 aa) (STJ192485) | Login | Anti-C1QTNF4 antibody (40-120 aa) (STJ192485) | ||||||||||||||||
|
||||||||||||||||||
Anti-B2M antibody (40-120 aa) (STJ192491) | Login | Anti-B2M antibody (40-120 aa) (STJ192491) | ||||||||||||||||
|
||||||||||||||||||
Anti-SLAMF6 antibody (20-100 aa) (STJ192494) | Login | Anti-SLAMF6 antibody (20-100 aa) (STJ192494) | ||||||||||||||||
|
||||||||||||||||||
Anti-SIGLEC9 antibody (10-90 aa) (STJ192501) | Login | Anti-SIGLEC9 antibody (10-90 aa) (STJ192501) | ||||||||||||||||
|
||||||||||||||||||
Anti-BAGE2 antibody (51-100 aa) (STJ192578) | Login | Anti-BAGE2 antibody (51-100 aa) (STJ192578) | ||||||||||||||||
|
||||||||||||||||||
Anti-SPON1 antibody (210-290 aa) (STJ192512) | Login | Anti-SPON1 antibody (210-290 aa) (STJ192512) | ||||||||||||||||
|
||||||||||||||||||
Anti-SARM1 antibody (281-330 aa) (STJ192592) | Login | Anti-SARM1 antibody (281-330 aa) (STJ192592) | ||||||||||||||||
|
||||||||||||||||||
Anti-FCGR3B antibody (90-170 aa) (STJ192518) | Login | Anti-FCGR3B antibody (90-170 aa) (STJ192518) | ||||||||||||||||
|
||||||||||||||||||
Anti-FCGR3A antibody (90-170 aa) (STJ192519) | Login | Anti-FCGR3A antibody (90-170 aa) (STJ192519) | ||||||||||||||||
|
||||||||||||||||||
Anti-CGB1 antibody (Internal) (STJ192524) | Login | Anti-CGB1 antibody (Internal) (STJ192524) | ||||||||||||||||
|
||||||||||||||||||
Anti-NPB antibody (1-50 aa) (STJ192603) | Login | Anti-NPB antibody (1-50 aa) (STJ192603) | ||||||||||||||||
|
||||||||||||||||||
Anti-LILRA1 antibody (Internal) (STJ192531) | Login | Anti-LILRA1 antibody (Internal) (STJ192531) | ||||||||||||||||
|
||||||||||||||||||
Anti-CALCR antibody (410-490 aa) (STJ192613) | Login | Anti-CALCR antibody (410-490 aa) (STJ192613) | ||||||||||||||||
|
||||||||||||||||||
Anti-RHCE antibody (161-210 aa) (STJ192535) | Login | Anti-RHCE antibody (161-210 aa) (STJ192535) | ||||||||||||||||
|
||||||||||||||||||
Anti-CCR10 antibody (120-200 aa) (STJ192615) | Login | Anti-CCR10 antibody (120-200 aa) (STJ192615) | ||||||||||||||||
|
||||||||||||||||||
Anti-CCR8 antibody (250-330 aa) (STJ192616) | Login | Anti-CCR8 antibody (250-330 aa) (STJ192616) | ||||||||||||||||
|
||||||||||||||||||
Anti-CCR9 antibody (140-220 aa) (STJ192617) | Login | Anti-CCR9 antibody (140-220 aa) (STJ192617) | ||||||||||||||||
|